Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases

Shigesaburo Miyakoshi, Masahiro Kami, Tetsuya Tanimoto, Takuhiro Yamaguchi, Hiroto Narimatsu, Eiji Kusumi, Tomoko Matsumura, Shinsuke Takagi, Daisuke Kato, Yukiko Kishi, Naoko Murashige, Koichiro Yuji, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shuichi Taniguchi

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

BACKGROUND. Myeloablative cord blood transplantation (CBT) for adult patients offers a 90% chance of engraftment with a 50% rate of transplant-related mortality, mostly attributable to infection. We have demonstrated the feasibility of reduced-intensity CBT (RI-CBT) for adult patients, in which cyclosporine was used for acute graft-versus-host disease (GVHD) prophylaxis. Transplantation-related mortality (TRM) was 27% within 100 days. Therefore our objective was to evaluate the feasibility of RI-CBT with tacrolimus as GVHD prophylaxis for adult patients with hematologic malignancies. METHODS. Thirty-four patients with a median age of 56.5 years (range; 22-68) with hematologic diseases underwent RI-CBT at Toranomon Hospital between November 2003 and September 2004. Preparative regimen comprised fludarabine 25 mg/m2 on days -7 to -3, melphalan 80 mg/m2 on day -2, and 4 Gy total body irradiation on day -1. GVHD prophylaxis was continuous intravenous infusion of tacrolimus 0.03 mg/kg, starting on day -1. RESULTS. Thirty-one patients achieved neutrophil engraftment at a median of day 20. Median infused total cell dose was 2.4×10E7/kg (range; 1.6-4.8). Thirty-two patients achieved complete donor chimerism at day 60. Grade II-IV acute GVHD occurred in 45% of patients, with a median onset of day 26. Primary disease recurred in five patients, and TRM within 100 days was 12%. Estimated 1-year overall survival was 70%. CONCLUSION. This study demonstrated the possible improvement in transplant-related mortality by tacrolimus as GVHD prophylaxis in adult RI-CBT recipients.

Original languageEnglish
Pages (from-to)316-322
Number of pages7
JournalTransplantation
Volume84
Issue number3
DOIs
Publication statusPublished - 2007 Aug 1
Externally publishedYes

Keywords

  • Acute graft-versus-host disease
  • Reduced intensity cord blood transplantation
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases'. Together they form a unique fingerprint.

Cite this